Clinical Trials Logo

Drug Resistance, Bacterial clinical trials

View clinical trials related to Drug Resistance, Bacterial.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06156956 Recruiting - Clinical trials for Drug Resistance, Bacterial

Fecal Microbiota Transplantation (FMT) to Decolonize Antibiotic - Resistant Bacteria (ARB) - New Protocol

STOP-ARB2
Start date: October 27, 2023
Phase: N/A
Study type: Interventional

The aim of the study is to assess the safety and efficacy of new protocol fecal microbiota transplantation (FMT) in the eradication of antibiotic resistant bacteria, including those featuring of resistance to new generation antibiotics. This study should answer the following research questions: 1. Will new treatment protocol and fully anaerobic FMT be effective in decolonization of ARB? 2. Will FMT improve the prognosis and quality of life in patients at high risk of ARB infection?

NCT ID: NCT03891433 Recruiting - Clinical trials for Urinary Tract Infections

Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae

CAPITIS
Start date: April 1, 2019
Phase: Phase 4
Study type: Interventional

This study evaluates the efficacy in achieving clinical cure in non-bacteremic urinary tract infections (UTI) caused by Escherichia coli or Klebsiella pneumoniae producers of extended-spectrum β-lactamases (ESBL) in adult patients. Half of participants will receive Piperacillin/Tazobactam as treatment, while the other half will receive Carbapenems. The investigators will verify that Piperacillin/Tazobactam is not inferior in achieving clinical cure, and that is not associated with a higher risk of adverse events in the directed treatment of non-bacteremic UTI compared to Carbapenems. The researchers hope to improve the use of antibiotics in the non-bacteremic UTI, reducing the "collateral damage" related to a deterioration in the prognosis of patients and the generation of resistant germs caused by the use of broad-spectrum antibiotics as carbapenems.